Financial Incentives to Improve Asthma (FINA)

Imperial College London logo

Imperial College London

Status

Completed

Conditions

Medication Adherence
Asthma in Children

Treatments

Behavioral: Financial incentives

Study type

Interventional

Funder types

Other

Identifiers

NCT05322044
22SM7433
306829 (Other Identifier)

Details and patient eligibility

About

The aim of this pilot randomised controlled trial is to assess the effectiveness of a short-term financial incentives intervention at bringing about behaviour change, namely short-medium term improvements in inhaled corticosteroid (ICS) adherence and asthma control in children and young people (CYP) with asthma.

Full description

After obtaining informed consent from parents (and assent from the CYP), CYP will be enrolled in a 24-week programme. All participants will receive an electronic monitoring device (EMD) which will be programmed with twice daily audio-visual reminders and will be required to download the EMD-associated App onto their smartphones. All participants will be required to attend 3 study visits at 0 weeks (baseline), 12-weeks and 24-weeks (follow-up). At baseline participants will be assessed for inhaler technique and given an asthma action plan (if they do not have one already) and will be randomised to either the control group or the intervention group. Intervention period will run between study visit 1 (0-weeks) and study visit 2 (12-weeks). Over the intervention period, participants in the intervention group will use their EMD with reminders, but will also be given financial incentives dependent upon their daily adherence and will have access to some additional EMD-associated app features (including notifications, a reward totaliser and a traffic light calendar to monitor progress). Control group participants will receive their usual care plus the use of EMD with reminders over the intervention period. After the intervention period (at study visit 2), intervention participants will no longer receive rewards or be able to access the additional app features. All participants (control and intervention) will be able to use their EMD with reminders for the final 12-week follow-up period. After completion of the 24-week programme, all participants will be required to return their EMD devices and will be invited to a focus group to share experiences and feedback of the trial.

Enrollment

32 patients

Sex

All

Ages

11 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Informed consent obtained from parent/guardian and assent from child.
  • CYP with doctor diagnosed asthma presenting to Emergency Department (ED) with a severe asthma exacerbation (as defined by ERS/ATS guidelines).
  • Aged between 11 and 17 years old
  • Prescribed maintenance inhaled corticosteroids (ICS) (which can include maintenance and reliever therapy MART) for at least 6-months.
  • Own their own mobile smartphone (running Android 8 or higher, or iOS 13 or higher)
  • Prescribed the following inhalers: Clenil, Flixotide, Symbicort, Seretide

Exclusion criteria

  • Parent/guardian / CYP unable to provide consent / assent
  • CYP with other, co-existing respiratory conditions
  • Parent/guardian/CYP who are not fluent or able to understand the information provided in English.
  • CYP who are involved in other intervention research studies (including CTIMPs)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

32 participants in 2 patient groups

Control (no financial incentive)
No Intervention group
Description:
No incentive. Usual care (plus EMD with reminders) for 12-weeks.
Intervention (financial incentive)
Experimental group
Description:
Financial incentive dependent upon daily medication adherence (plus EMD with reminders) for 12-weeks.
Treatment:
Behavioral: Financial incentives

Trial contacts and locations

1

Loading...

Central trial contact

Jasmine Hine; Louise Fleming

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems